A PORSOLT COMPANY

Porsolt expanded its in vitro drug discovery service capabilities in December 2015 with the acquisition of Fluofarma.

Porsolt is a long established preclinical CRO with an international reputation for expertise in physio-pathological models, customized procedures, and tailored solutions for discovering treatments in multiple disease areas, including psychiatric and neurological disorders, acute and chronic pain, inflammation, cardiac and vascular diseases, metabolic and eating disorders, and dermatology, using disease models in multiple species. Porsolt also provides GLP safety evaluation of drug candidates from screening to regulatory studies before first-in-man administration, including full assessment of arrhythmogenic risk and abuse and dependence liability. The acquisition further expands Porsolt’s capabilities and services that can assist clients at earlier stages of their drug discovery programs.